We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone

By LabMedica International staff writers
Posted on 16 Apr 2025

"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. More...

However, detecting the mutational signatures of cancer from tiny amounts of tumor DNA in blood samples has posed significant challenges. Now, a new study published in Nature Methods introduces a new error-corrected method for cancer detection from blood samples that is far more sensitive and accurate than previous techniques, potentially offering a valuable tool for monitoring disease status in patients after treatment.

For nearly a decade, researchers at Weill Cornell Medicine (New York, NY, USA) and the New York Genome Center (NYGC, New York, NY, USA) have been working on methods based on whole-genome sequencing, rather than the more traditional approach of targeted sequencing focused on specific regions of DNA where mutations are expected. In a prior study, they demonstrated that it was possible to detect advanced melanoma and lung cancer in blood samples from patients, even without access to sequence data from the tumors. In their most recent study, the researchers benchmarked the performance of a new commercial sequencing platform developed by Ultima Genomics (Fremont, CA, USA). They showed that this affordable platform offers a high “depth” of coverage, meaning high-quality sequencing data, which enables the detection of extremely low concentrations of circulating tumor DNA. By incorporating an error-correcting method, they significantly enhanced the accuracy of the technique.

In this study, the researchers first highlighted that the low cost of the new sequencing platform enables whole-genome sequencing at a depth that would have been too expensive with older technologies. Using this platform alone, and guided by known mutational patterns from patient tumors, they were able to detect tumor DNA in blood samples at concentrations as low as part per million. The blood samples used in the study were collected after obtaining informed consent from the patients. The team then improved the accuracy of the approach with an error-correction method that leverages the redundant information in natural two-stranded DNA. They demonstrated that the combined technique offers remarkably low error rates, making it feasible to use on blood samples even without access to tumor tissue. In collaboration with other research groups, the team successfully applied this high-sensitivity, low-error method to detect and assess very low levels of cancer in patients with bladder cancer and melanoma using blood samples alone.

“We’re now entering an era of low-cost DNA sequencing, and in this study, we took advantage of that to apply whole-genome sequencing techniques that in the past would have been considered wildly impractical,” said senior author Dr. Dan Landau. “These results allow us to think about a future in which we can detect and track cancer from blood tests alone.”

Related Links:
Weill Cornell Medicine
NYGC
Ultima Genomics


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Creatine Kinase-MB Assay
CK-MB Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.